R.N. Collins has written a series of 20 new articles for cannabis law report on 2026 Psychedelics & Legal Issues.

This is the fourth

Independent Oversight Structures for Psychedelic Service Centers

Policy Reform / Governance / Oversight Series

Author RN Collins

Contact: https://www.linkedin.com/in/rn-collins/

EXECUTIVE SUMMARY

Psychedelic service centers — the licensed facilities where adults consume psilocybin or other regulated natural medicines under the supervision of a trained facilitator — are the principal site of consumer protection risk in every state psychedelic regulatory program. They are also the least developed component of existing oversight frameworks. Oregon’s Oregon Psilocybin Services (OPS) section, Colorado’s split DORA/Department of Revenue structure, and New Mexico’s Department of Health regulatory program each establish licensing requirements for service centers but have not yet developed robust, independent oversight mechanisms for ongoing operational compliance. Data from Oregon’s program — which, as of Q3 2025, has seen the closure of twelve service centers since early 2024, a greater-than-99.6 percent incident-free session rate, and a pending federal ADA lawsuit challenging the program’s structural exclusion of homebound disabled clients — illustrates both the early safety profile of regulated programs and the structural access and compliance gaps that independent oversight must address.¹

This article examines the components of effective independent oversight for psychedelic service centers: (I) the specific risks that service center oversight must address; (II) existing oversight mechanisms and their limitations; (III) independent advisory board structures and their function; (IV) complaint intake, investigation, and disciplinary processes; (V) inspection regimes appropriate for the psychedelic context; (VI) data transparency and public reporting requirements; (VII) the ADA access obligation and its implications for oversight design; and (VIII) recommendations for a model independent oversight structure.

The central argument of this article is that psychedelic service centers require a form of oversight that is neither purely commercial-regulatory nor purely clinical-therapeutic but draws on both traditions. The unusual characteristics of a psilocybin administration session — involving an altered state of consciousness, a sustained facilitator-client relationship, and significant psychological vulnerability — create risks that standard commercial license oversight (periodic inspections, complaint investigation, license renewal) cannot adequately address without supplementary mechanisms including independent client advocacy, structured safety monitoring, and sector-specific ethics enforcement.

I. THE SPECIFIC RISKS THAT SERVICE CENTER OVERSIGHT MUST ADDRESS

A. Therapeutic Boundary Violations

The most serious risk in psychedelic service center settings is the violation of therapeutic boundaries, including sexual contact between facilitators and clients. This risk is not hypothetical. The broader psychedelic therapy literature documents that the altered state of consciousness induced by psychedelic substances creates significant vulnerability that malicious or insufficiently trained facilitators can exploit. The MAPS-sponsored MDMA clinical trial program produced at least one documented and formally adjudicated case of sexual misconduct: Richard Yensen engaged in a sexual relationship with participant Meaghan Buisson during and after a Phase II MDMA clinical trial on Cortes Island, British Columbia, with the knowledge of co-therapist Donna Dryer; MAPS formally acknowledged the violation in a 2019 public statement, both investigators were barred from all MAPS-related activities, and Dryer subsequently resigned her medical license.² The history of early MDMA-assisted therapy in the 1980s provides additional documentation of the systemic character of this risk: psychiatrist Richard Ingrasci was permanently barred from practice in 1989 after patients alleged sexual abuse while under MDMA’s influence, and Maryland psychiatrist Francesco DiLeo faced equivalent disciplinary proceedings two years earlier — both figures were pioneers in the same therapeutic movement that produced the clinical frameworks now underpinning state psilocybin programs.³ These documented incidents across multiple practitioners and decades establish that boundary violation risk in psychedelic therapeutic contexts is not an isolated aberration but a recurring pattern that regulatory frameworks must structurally address.

Oregon’s OPS rules explicitly address facilitator conduct, including requirements related to informed consent and prohibited behaviors.⁴ However, explicit statutory prohibition of sexual contact between facilitators and clients — with mandatory license revocation as the minimum consequence — has not been codified in any existing state psilocybin statute. This omission creates ambiguity about the severity of consequences for the most serious category of client harm.

MAPS’ institutional response to documented misconduct in its clinical trial program, including the development of a Code of Ethics for Psychedelic Psychotherapy and a Compliance Team with investigation and recommendation authority, illustrates the kind of sector-specific ethics infrastructure that state regulatory frameworks must establish for licensed service centers.⁵ On January 25, 2022, the Board of Directors of MAPS PBC adopted a charter to form an Independent Ethics Review Board (IERB) — separate from Institutional Review Boards that govern clinical trial compliance — representing a model for the broader psychedelic services sector.⁶

B. Physical Safety During Administration Sessions

Oregon’s Q1 2025 data reported a greater-than-99.6 percent incident-free session rate across approximately 1,509 clients, with no product recalls and no reported post-session adverse reactions in the data set.⁷ This early safety profile is encouraging but must be interpreted cautiously: the OPS data collection framework requires adverse events to be initiated by the client, with no requirement for proactive follow-up by service centers or facilitators after the 72-hour mark.⁸ Clinical trial protocols for psilocybin, by contrast, typically require structured clinician-led follow-ups at set intervals. A three-round e-Delphi study cited in a 2025 Johns Hopkins Bloomberg School of Public Health report on psychedelic policy identified follow-ups at 1 to 2 weeks, 6 months, and 12 months as priority items for supervised psilocybin safety monitoring — a timeline that no state program currently mandates.⁹

The OPS Q1 2025 data analysis noted that current data collection appears to end at the 72-hour mark, raising questions about longer-term outcomes.¹⁰ This passive adverse event reporting may systematically undercount delayed-onset psychological reactions, including cases of hallucinogen persisting perception disorder (HPPD), mania triggered by psilocybin in clients with undiagnosed bipolar disorder, and anxiety or depression exacerbations.

C. Medication Contraindications and Screening Failures

Psilocybin has clinically significant interactions with serotonergic medications — including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and lithium — as well as with antipsychotic agents. Colorado explicitly recognizes this risk by requiring that general facilitators screen prospective clients against a protocol that identifies individuals requiring “a higher level of care by medical or mental health providers,” including persons taking antipsychotic medications, who must see a clinical facilitator.¹¹

Oregon’s preparation session requirement obligates facilitators to review client health history, but the OPS rules do not specify a standardized contraindication screening protocol that regulators can verify through inspection. A service center that conducts inadequate contraindication screening before an administration session creates serious risks of serotonin syndrome, psychosis, or dangerous behavioral responses — risks that become oversight failures when regulators lack visibility into the screening process.

D. Physical Access and ADA Compliance

Oregon’s service center location restrictions — prohibiting centers within incorporated city or town limits and in exclusively residential zones — have produced a documented pattern of physical inaccessibility for persons with disabilities. In Cusker et al. v. Oregon Health Authority, No. 6:2024cv00998 (D. Or.), U.S. District Judge Mustafa T. Kasubhai denied the OHA’s motion to dismiss in a 12-page ruling issued May 30, 2025, establishing that the ADA applies to Oregon’s psilocybin program and that requiring equal physical access would not constitute an order to distribute a federally controlled substance.¹² The court’s reasoning, analogizing to Smith v. 116 S Market LLC (9th Cir. 2020), concluded that requiring physical access accommodation “rests on physical access rather than use or distribution of a controlled substance in violation of state and federal laws.”¹³

The OHA filed a Motion for Judgment on the Pleadings in October 2025, arguing that the plaintiffs lack standing to raise ADA claims on behalf of their disabled clients — a procedurally distinct motion from the earlier motion to dismiss.¹⁴ Regardless of the ultimate outcome, the Cusker litigation illustrates a structural oversight failure: the existing OPS regulatory framework provided no mechanism for disabled clients to bring accessibility grievances to a regulatory body before resort to federal litigation. An effective independent oversight structure must include an accessible complaint process for clients who cannot physically access service centers.

E. Market Contraction and Provider Solvency

Oregon’s program has experienced meaningful market contraction: by Q3 2025, twelve service centers had closed since early 2024, leaving only twenty-three of the thirty-five licensed centers still operational.¹⁵ A key factor driving this contraction is high operational costs — including the $10,000 annual license fee, mandated security infrastructure, and stringent storage protocols — combined with declining product prices and limited client volumes.¹⁶ Oregon had to draw $3.1 million from the state general fund to operate the program in the 2023–25 biennium, and the OHA has requested $6.6 million in general fund support for the 2025–27 biennium after the Legislature declined to appropriate new funding — a fiscal position that raises structural questions about the program’s ability to sustain any independent oversight layer without a dedicated funding source.¹⁷

When a service center closes, clients who are mid-course in their preparation-administration-integration sequence face abrupt service interruption. Oregon’s oversight framework does not currently include provisions requiring service centers to provide advance notice to clients and coordinate transfer of care before closure, nor does it require service centers to maintain reserve funds sufficient to fulfill outstanding client commitments. These continuity-of-care obligations, common in other regulated healthcare settings, are absent from the existing psilocybin service center oversight framework.

II. EXISTING OVERSIGHT MECHANISMS AND THEIR LIMITATIONS

A. Oregon’s OPS Compliance Infrastructure

Oregon’s OPS administrative rules establish a compliance investigation framework, including a new compliance investigation rule that became effective January 1, 2025.¹⁸ OPS’s stated enforcement authority extends to investigating complaints, incidents, and concerns related to safety issues or statute and rule violations that occur on licensed premises and during the provision of psilocybin services.¹⁹ The 2025 rules also added a temporary rule, effective August 29, 2025, addressing a discovered loophole in service center hours-of-operation rules — demonstrating that OPS actively monitors compliance but primarily reacts to discovered vulnerabilities rather than proactively assessing operational risk.²⁰

Oregon’s OPS rulemaking process includes Rules Advisory Committees (RACs) that convene subject-matter experts, affected licensees, and community representatives to review and comment on draft rules.²¹ The RAC process includes racial and fiscal impact evaluation of proposed rules.²² These governance mechanisms are valuable for rulemaking but do not constitute independent operational oversight of service centers.

The Oregon Psilocybin Advisory Board (OPAB) was established by Measure 109 to advise OHA but has no independent enforcement authority. Its advisory role is limited to making policy recommendations during the rulemaking process — under ORS 475A, OPAB submits recommendations to OHA, and OHA publishes letters explaining which recommendations it adopted and which it declined. The OPS rulemaking process is described as being “informed by” OPAB recommendations, alongside RAC input and public comment, but OHA leadership retains final authority over rule adoption and is not required to adopt OPAB recommendations.²³ The absence of a formal accountability loop — requiring OHA to publicly justify any deviation from an OPAB recommendation — limits OPAB’s functional influence on outcomes and leaves a structural gap between advisory engagement and operational accountability. An independent oversight body with authority to receive client complaints, conduct unannounced inspections, and recommend disciplinary action remains absent from Oregon’s oversight architecture.

B. Colorado’s Advisory Board and Split-Agency Model

Colorado’s Natural Medicine Advisory Board (NMAB) played a substantive policy role in the regulatory development process: the board produced 123 formal recommendations across 75 meetings over eight months before officially adopting its consolidated recommendations on January 19, 2024 — a milestone representing the most comprehensive advisory engagement in any state natural medicine program.²⁴ DORA and DOR then converted those recommendations into draft rules through a public rulemaking process conducted between March and July 2024.²⁵

The NMAB’s recommendations were not uniformly adopted. The most significant governance friction emerged over at-home facilitation: the NMAB’s Public Health and Health Equity subcommittee adopted a recommendation in December 2023 that the state develop regulations permitting natural medicine services in private residences, and the full NMAB adopted this recommendation in January 2024 as part of its consolidated recommendations.²⁶ DORA nonetheless made substantial late changes to proposed rules in November 2024 — just days before the final rulemaking hearing — that stakeholders and the NMAB characterized as substantially restricting at-home access in ways that contradicted the board’s recommendation, raising concerns about violation of Colorado’s administrative notice requirements and undermining public trust in the process.²⁷ DORA subsequently withdrew the controversial changes before submitting remaining cleanup rules, then opened a new rulemaking proceeding on at-home facilitation.²⁸ This episode illustrates both the substantive influence that a well-organized advisory board can exercise and the structural limits of advisory authority when agencies retain final rulemaking discretion without a mandatory justification requirement for departures from board recommendations.

As of early 2026, the program is too new to have developed a compliance investigation track record from which lessons can be drawn, but the split-agency structure creates potential accountability gaps at the DORA/DOR interface for issues that span facilitator conduct and facility operations.

C. New Mexico’s Medical Model

New Mexico’s Medical Psilocybin Advisory Board, established by SB 219 and convening for the first time on December 5, 2025, is the newest advisory structure in any operational state psilocybin program.²⁹ The board’s composition, including Indigenous advocates and medical specialists, and the DOH’s stated intent to accelerate program implementation reflect attention to both equity and clinical safety.³⁰ However, as a newly established advisory body with no inspection or enforcement history, the New Mexico oversight architecture is still being designed.

III. INDEPENDENT ADVISORY BOARD STRUCTURES AND PERFORMANCE

A. Functions of an Effective Advisory Board

The existing state psilocybin advisory boards — Oregon’s OPAB, Colorado’s NMAB, and New Mexico’s Medical Psilocybin Advisory Board — share a common structural limitation: they are advisory bodies to regulatory agencies and lack independent enforcement authority. Their utility is primarily in rulemaking input and policy recommendation.

Effective independent oversight of psychedelic service centers requires a distinct institutional function that goes beyond advisory rulemaking input. Drawing on analogies from other regulated healthcare contexts — the Joint Commission’s independent accreditation of hospitals; state attorneys general’s enforcement of nonprofit fiduciary obligations; independent patient ombudsman programs in Medicaid managed care — the model oversight structure proposed here includes an independent oversight body with both advisory and investigative functions.

B. Composition Requirements

An effective independent oversight body for psychedelic service centers should include representatives with expertise in: psychedelic pharmacology and clinical practice; trauma-informed therapy; disability rights and ADA compliance; public health and epidemiology; Indigenous and traditional healing practices; ethics and professional conduct; client safety and advocacy; and legal/regulatory affairs. The body should include at minimum two members with lived experience of psychedelic services as clients.

Critically, members of the independent oversight body should be prohibited from holding any financial interest in licensed psilocybin businesses during their term of service and for a specified period after departure, consistent with the ethics requirements applicable to gaming and utility commissioners. The prohibition should extend to immediate family members and should be enforced through annual financial disclosure requirements.

C. Advisory Board Performance and Accountability Mechanisms

California’s SB 1012 (2023-2024 Regular Session), though not enacted, proposed one of the most detailed independent oversight frameworks for psychedelic services in any state legislative text. The bill would have established a Board of Regulated Psychedelic Facilitators with authority to establish educational and training qualifications; required an Expert Oversight Committee to publish annual public reports on whether recommendations were implemented; and mandated a complaint, review, and disciplinary process for facilitators who engage in misconduct.³¹ The bill’s requirement for annual public reporting on the agency’s response to oversight committee recommendations — creating a documented accountability loop between the independent advisory body and the regulatory agency — addresses the structural gap identified above in Oregon’s OPAB framework. Colorado’s at-home facilitation episode illustrates the practical significance of this accountability mechanism: had DORA been required to publicly justify any departure from a NMAB recommendation in writing before a final rulemaking hearing, the late reversal of established recommendations would have been procedurally more difficult.

All state psilocybin programs should adopt the following minimum accountability framework for advisory boards: (a) when the licensing agency declines to adopt or substantially modifies a recommendation from the independent advisory body, it must publish a written statement of reasons within 60 days of the final rule adoption; (b) the advisory body should publish an annual public report summarizing its recommendations, the agency’s disposition of each, and the body’s assessment of whether the agency’s responses adequately addressed the underlying concerns; and (c) the advisory body should have standing to request judicial review of agency rule adoptions that the body believes substantially contradict its formal recommendations, with the burden on the agency to demonstrate that the deviation was based on a material factual or legal consideration not addressed in the recommendation.

IV. COMPLAINT INTAKE, INVESTIGATION, AND DISCIPLINARY PROCESSES

A. The Existing Gap

Oregon’s OPS rules contemplate complaint investigation but do not establish a publicly accessible, standardized complaint intake process visible to clients. There is no independent client advocate function — no dedicated ombudsman or advocacy office within or adjacent to OPS — and no publicly posted information explaining how clients can report facilitator misconduct or service center violations without fear of retaliation.

B. Model Complaint Framework

The model independent oversight structure recommends: (1) a publicly accessible, multilingual complaint intake portal available to clients, family members, facilitators, and any other individual with knowledge of a potential violation; (2) a written complaint acknowledgment within 5 business days; (3) an initial triage determination within 30 days classifying the complaint as requiring immediate investigation (conduct involving risk to client safety), standard investigation (regulatory or administrative violations), or advisory resolution (non-investigable concerns); (4) formal findings issued within 90 days for standard investigations, with this timeline to be phased in proportionate to program scale — the 90-day requirement should not take effect until the licensing agency has reached a minimum staffing benchmark sufficient to support concurrent investigations without compromising active licensing functions; (5) a confidential reporting pathway for facilitators who witness misconduct by colleagues, with explicit anti-retaliation protections; and (6) an annual public report aggregating complaint data by type, resolution category, and demographic characteristics of complainants, without personally identifying information.

Disciplinary dispositions should be made public, consistent with the public accountability norms applicable to licensed healthcare providers in other sectors. License revocations, suspensions, and consent orders should be posted on the licensing agency’s public website with a searchable database indexed by licensee name and license number.

C. Mandatory Incident Reporting

Oregon currently requires follow-up contact with clients within 72 hours of an administration session and requires service centers to report adverse events — but adverse event reporting is client-initiated rather than facilitator- or service-center-initiated.³² The model oversight structure recommends mandatory facilitator-initiated adverse event reporting within 24 hours for any incident involving: (a) emergency medical services contact; (b) psychiatric crisis; (c) physical injury; (d) any allegation of sexual contact or boundary violation; (e) client elopement from the service center during an administration session; or (f) any product quality complaint requiring quarantine. Mandatory reporting should be to the state licensing agency and, for events involving clinical emergencies, to the relevant local health authority.

V. INSPECTION REGIMES FOR THE PSYCHEDELIC CONTEXT

A. The Limitations of Standard Commercial Inspections

Standard commercial license inspection models are insufficient for psychedelic service centers. The core compliance risks in a service center — facilitator conduct during an administration session, adequacy of informed consent, quality of preparation and integration sessions, client screening for contraindications — are not observable through a traditional floor inspection. An inspector arriving at a service center between sessions can verify that fire suppression systems are operational and that storage protocols are being followed, but cannot assess whether the facilitator is providing adequate preparation session support or whether the consent process is genuinely informed.

The limitations of standard external inspection models in therapeutic-context settings are well documented in the healthcare regulation literature. A systematic Cochrane review examining external inspection of compliance in healthcare organizations found that the evidence for external inspection improving actual quality-of-care outcomes — as opposed to improving compliance with documented standards — was very low certainty, and that inspection-based approaches are most effective when they address verifiable structural and process standards rather than relationship-based professional conduct.³³ Psychedelic service center oversight must account for this limitation explicitly: the inspection regime appropriate for verifying storage compliance and physical accessibility is structurally inadequate for assessing whether the most serious risks — boundary violations, inadequate emotional support during crisis, coercive suggestion during altered states — are being controlled.

B. Model Inspection Framework

The model oversight structure recommends a tiered inspection framework comprising three components:

Tier 1: Pre-Opening Inspection. Before a newly licensed service center begins accepting clients, an OPS or DORA-designated inspector should conduct an on-site review of physical premises compliance, required signage, consent documentation systems, emergency contact protocols, and required drug storage infrastructure.

Tier 2: Annual Operational Inspection. On an annual basis, each licensed service center should be subject to an unannounced inspection covering physical premises; review of a sample of client intake forms and screening documentation for completeness; review of adverse event logs; review of social equity plan implementation; and confirmation that all active facilitators hold current licenses in good standing.

Tier 3: Documentation Audits. On a rotating two-year cycle, the licensing agency should conduct a documentation audit of a randomly selected sample of service centers covering informed consent forms, administration session logs, adverse event reports, facilitator continuing education records, and SB 303-mandated data forms (in Oregon) or equivalent. Documentation audits should be conducted remotely and should be designed to identify systemic compliance patterns rather than individual violations.

C. Peer Review and Structured Consultation Requirements

Several state professional licensing bodies use peer review programs to assess professional practice quality in contexts where the primary risks are relational rather than mechanical. The model oversight structure does not recommend test-client programs for routine oversight given the ethical complexity of simulating altered states. However, the model recommends that the licensing agency develop and require service centers to participate in structured peer review programs — similar to the peer consultation networks used by therapists and other mental health professionals — in which facilitators present and discuss case material in supervised group settings with other licensed facilitators. Participation in peer review should be a condition of license renewal.

The governance of peer review programs requires specification that the article’s core oversight recommendations have not previously addressed. Peer review groups should be: (a) convened by OPS-approved peer review organizations or associations, subject to licensing agency criteria for approval; (b) composed of a minimum of three licensed facilitators per group, with at least one member having two or more years of practice experience; (c) documented through standardized session logs submitted to the licensing agency as part of license renewal; and (d) subject to audit by the licensing agency to verify that participation is substantive rather than nominal. Facilitators who cannot be placed in a peer review group due to geographic isolation should be entitled to an alternative consultation format — individual supervision with an approved clinical supervisor — as an equivalent option, to avoid the rural access penalty that a rigid group-participation requirement could create.

VI. DATA TRANSPARENCY AND PUBLIC REPORTING

A. Oregon’s Quarterly Data Initiative

Oregon’s OHA began publishing quarterly psilocybin program data in mid-2025, with the first dataset covering January through April 2025.³⁴ This quarterly reporting initiative is the first of its kind in any state psychedelic program and represents a significant advance in program transparency. The data includes product sales volume, client demographic characteristics, session types and formats, and incident data. Psychedelic Alpha’s tracker updates this data progressively with visualization and contextual analysis.³⁵

The quarterly data initiative has limitations. Data collection ends at 72 hours post-session. Client demographic data is subject to opt-out. Service center closure data must be triangulated from licensing records rather than being directly reported.³⁶ Pricing data is not systematically collected, leaving the equity dimensions of access (who can afford services) only partially visible.

B. Model Transparency Requirements

The model independent oversight structure recommends statutory requirements for: (1) quarterly publication of aggregate program data covering session volume, license counts by type and status, adverse event counts by severity category, and complaint counts by type; (2) annual publication of a demographic equity report analyzing client demographic characteristics against the state’s overall population and the communities most affected by prior drug enforcement; (3) public disclosure of all license suspensions and revocations within 30 days of the disciplinary action becoming final; (4) publication of hearing officer decisions in all contested disciplinary proceedings, with identifying information redacted for clients and facilitators who are not respondents; and (5) a biennial program evaluation report, prepared by an independent academic or nonprofit entity (not the licensing agency itself), assessing program outcomes against the statutory purposes of the enabling legislation.

VII. THE ADA ACCESS OBLIGATION AND ITS IMPLICATIONS FOR OVERSIGHT

A. Cusker v. OHA and the Scope of the Access Obligation

The Cusker litigation has established that Title II of the ADA applies to Oregon’s state-operated psilocybin services program. District Judge Kasubhai’s May 30, 2025 ruling denying the OHA’s motion to dismiss held that the plaintiffs’ requested remedy — requiring the OHA to develop a process for homebound disabled clients to access psilocybin services — rests on physical access rather than distribution of a controlled substance, and therefore does not require the court to order a violation of federal or state controlled substance law.³⁷

The implications extend beyond Oregon. Any state that operates a psilocybin services program is subject to the ADA as a public entity under Title II, 42 U.S.C. § 12132. This means the program must make reasonable modifications to its policies, practices, and procedures to avoid discriminating against persons with disabilities, unless doing so would fundamentally alter the nature of the program or impose an undue burden.³⁸ Service centers that receive state authorization operate within the state’s regulatory framework and may themselves be subject to Title III ADA requirements as places of public accommodation.

Colorado’s DORA considered in-home services during its rulemaking process but proposed limiting home services to persons requiring palliative care — a restriction that may be insufficient to satisfy the full ADA accommodation obligation if persons with physical impairments or other conditions that prevent travel to a service center request reasonable modification.³⁹

B. ADA Compliance as an Oversight Function

The model oversight structure recommends that the independent oversight body include a dedicated ADA access compliance function, separate from the general complaint intake process, that: (1) reviews all proposed service center rules and regulations for ADA compatibility before adoption; (2) maintains a publicly posted reasonable modification request process for clients who cannot physically access licensed service centers due to disability; (3) coordinates with the state licensing agency to develop standard protocols for in-home or community-based service delivery as a reasonable accommodation; and (4) publishes an annual ADA compliance report. The independent oversight body should be authorized to bring a compliance action against the licensing agency itself if the agency fails to develop reasonable accommodation protocols within a specified period.

VIII. RECOMMENDATIONS FOR A MODEL INDEPENDENT OVERSIGHT STRUCTURE

Drawing on the analysis above, the model independent oversight structure for psychedelic service centers includes the following components:

1. An Independent Oversight Body with Dual Functions. The oversight body should have both an advisory function (participating in rulemaking, reviewing proposed regulations for safety and equity impacts) and an investigative function (receiving and investigating complaints, conducting documentation audits, issuing findings). It should not be a subcommittee of the licensing agency but should have statutory independence, with members subject to fixed terms, removal-for-cause protections, and comprehensive financial conflict-of-interest requirements.

2. A Client Advocate Office. A dedicated client advocate function — modeled on Medicaid managed care ombudsman programs — should be established within or adjacent to the oversight body. The client advocate should have authority to assist clients in navigating the complaint process, request records on behalf of complainants, and file complaints directly with the oversight body when client advocacy efforts are ineffective.

3. Dedicated Funding Mechanism. The independent oversight body must have a sustainable, dedicated funding source independent of the licensing agency’s general budget and protected from displacement by licensing fee reductions. The model framework recommends that the oversight body be funded by a dedicated percentage — not less than 10 percent — of annual licensing fee revenues, deposited into a ring-fenced oversight fund, with a minimum statutory floor established at program launch to ensure adequate capitalization during early low-revenue years. Oregon’s experience — where $3.1 million in general fund support was required for the 2023–25 biennium and a further $6.6 million has been requested for 2025–27, while licensing revenues remain well below program costs — illustrates that relying on fee revenue alone without a statutory minimum appropriation or floor will produce an oversight body that cannot fulfill its mandate during the critical early years of program operation.⁴⁰

4. Advisory Board Accountability Mechanism. A requirement that the licensing agency publish written reasons within 60 days for any deviation from formal oversight body recommendations, and that the oversight body publish an annual report documenting its recommendations and the agency’s dispositions. This accountability loop addresses the structural gap between advisory engagement and enforceable accountability that characterizes all three current state programs.

5. Mandatory Adverse Event Reporting. Facilitators and service centers should be required to report adverse events within 24 hours using a standardized reporting form, replacing the current client-initiated passive reporting framework.

6. Tiered Inspection Program. Pre-opening inspections, annual unannounced operational inspections, and biennial documentation audits, as described in Section V.

7. Peer Review Program with Specified Governance. All licensed facilitators required to participate in OPS-approved peer review groups as a condition of license renewal; peer review organizations subject to licensing agency approval criteria; documented session logs submitted with renewal applications; remote individual supervision as an alternative for facilitators who cannot access a geographic peer review group.

8. Public Disciplinary Database. All license actions — suspensions, revocations, consent orders, and voluntary surrenders in lieu of discipline — should be published in a searchable public database within 30 days of becoming final.

9. ADA Compliance Function. The oversight body should include a dedicated ADA compliance review function with authority to review proposed regulations and develop reasonable accommodation protocols.

10. Enhanced Transparency Requirements. Quarterly aggregate data publication; annual equity demographic report; biennial independent program evaluation; public hearing officer decisions.

11. Continuity of Care for Voluntary Closure. Service centers facing voluntary closure should be required to provide 90 days’ advance notice to the licensing agency, to clients with active service arrangements, and to the client advocate office, and to coordinate transfer-of-care for clients who are mid-course in their preparation-administration-integration sequence.

12. Continuity of Care for Involuntary Closure. Voluntary closure provisions cannot apply when a service center’s license is revoked for cause or surrendered under regulatory compulsion — scenarios that may be among the most disruptive to active clients precisely because they arise without advance planning. When a license is revoked or involuntarily surrendered, the licensing agency should immediately trigger a mandatory client notification obligation, requiring the service center operator to notify all clients with active or pending service arrangements within 24 hours of the revocation becoming effective. The licensing agency should simultaneously activate a mandatory referral protocol — administered by the licensing agency or the client advocate office, not the now-unlicensed operator — providing each affected client with a list of currently licensed service centers within a defined geographic radius and, for clients in active administration sequences, a prioritized transfer-of-care placement administered within 72 hours of notification. The licensing agency should maintain a real-time registry of service centers with available capacity to receive transfer clients, updated on a quarterly basis, to enable rapid activation of this protocol.

13. Sexual Misconduct Prohibition. The enabling statute should explicitly prohibit sexual contact between facilitators and clients at any time — including during integration sessions held outside the service center — and should specify mandatory license revocation as the minimum consequence, regardless of consent claims.

ENDNOTES

1. Psychedelic Alpha, The Oregon Psilocybin Services Tracker (updated through Q3 2025), https://psychedelicalpha.com/data/the-oregon-psilocybin-services-tracker (noting 12 center closures since early 2024, 23 of 35 licensed centers operational as of Q3 2025, greater-than-99.6% incident-free session rate); Cusker et al. v. Oregon Health Authority, No. 6:2024cv00998 (D. Or. May 30, 2025) (motion to dismiss denied).
2. MAPS, Statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators (May 24, 2019), https://maps.org/2019/05/24/statement-public-announcement-of-ethical-violation-by-former-maps-sponsored-investigators/ (documenting that Yensen engaged in a sexual relationship with participant Meaghan Buisson during and after a MAPS Phase II MDMA clinical trial; both investigators barred from MAPS-related activities; Dryer subsequently resigned her medical license); Pharmacy Times, MDMA Rejected: The Story of a Study Participant Entrenched in Ethical Violations (Feb. 28, 2025), https://www.pharmacytimes.com/view/mdma-rejected-the-story-of-a-study-participant-entrenched-in-ethical-violations-and-a-data-breach (describing the Buisson matter and subsequent FDA complete response letter for MDMA capsules in August 2024); CBC News, As Psychedelic Therapy Goes Mainstream, Former Patient Warns of Danger of Sexual Abuse (Mar. 18, 2021), https://www.cbc.ca/news/canada/british-columbia/bc-sexual-abuse-psychedelic-therapy-1.5953480 (reporting Buisson’s civil claim filed in B.C. Supreme Court in 2018 alleging repeated sexual assault by Yensen with Dryer’s knowledge; civil claim settled on undisclosed terms in June 2019).
3. Mad in America, Set, Setting, Forgetting: Silence on Abuse in Psychedelic Therapy Histories (Dec. 20, 2024), https://www.madinamerica.com/2024/12/set-setting-forgetting-silence-on-abuse-in-psychedelic-therapy-histories/ (describing 1989 permanent license bar of psychiatrist Richard Ingrasci following patient allegations of sexual abuse under MDMA influence; 1987 disciplinary proceedings against Maryland psychiatrist Francesco DiLeo for equivalent violations; both figures among the early American proponents of MDMA-assisted therapy); CBC News, supra note 2 (noting that the allegations against Yensen and Dryer “are not outliers in the field of psychedelic therapy, where sexual abuse has long been acknowledged as a potential risk”).
4. Oregon Health Authority, Oregon Psilocybin Services — Administrative Rules (updated Jan. 2026), https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-administrative-rules.aspx (OPS rules covering facilitator conduct, client safety planning, informed consent, and prohibited behaviors under OAR 333-333 et seq.).
5. MAPS, Cultivating Safety in Psychedelic Therapy, https://maps.org/news/bulletin/cultivating-safety-in-psychedelic-therapy/ (describing MAPS Code of Ethics for Psychedelic Psychotherapy, Compliance Team structure and investigation authority, and mandatory ethics training for MDMA therapy providers).
6. MAPS PBC, MAPS PBC Adopts Charter for Independent Ethics Review Board (Feb. 2, 2022), https://maps.org/2022/02/02/maps-pbc-adopts-charter-for-independent-ethics-review-board/ (Board of Directors of MAPS PBC adopted charter on January 25, 2022, to form an Independent Ethics Review Board separate from Institutional Review Boards governing clinical trial compliance; charter mandated independent experts in ethics and psychotherapy plus survivor advocate).
7. Psychedelic Alpha, Oregon Psilocybin Services Tracker: Q1 2025 (Oct. 10, 2025), https://psychedelicalpha.com/news/oregon-psilocybin-services-tracker-q1-2025 (reporting greater-than-99.6% incident-free session rate for 1,509 clients in Q1 2025); Oregon Health Authority, Oregon Psilocybin Services Publishes Interactive Data Dashboard (June 2025), https://www.oregon.gov/oha/erd/pages/oregon-psilocybin-services-publishes-interactive-data-dashboard.aspx (1,509 clients served January–April 2025; six experiencing behavioral, medical, or post-session reactions).
8. Psychedelic Alpha, Oregon Psilocybin Services Tracker: Q1 2025, supra note 7 (noting adverse events “must be initiated by the client, with no requirement for proactive follow-up by the service center or facilitator” beyond the 72-hour window).
9. Johns Hopkins Bloomberg School of Public Health, Psychedelic Policy for Maryland: An Independent Report (Oct. 2025), https://hbhi.jhu.edu/sites/default/files/2025-11/Psychedelic%20Policy%20for%20Maryland_JHU_Report.pdf (citing three-round e-Delphi study defining priority items for supervised psilocybin services data collection, including follow-ups at 1–2 weeks, 6 months, and 12 months as priority safety monitoring items).
10. Psychedelic Alpha, Oregon Psilocybin Services Tracker: Q1 2025, supra note 7 (noting current data collection ends at 72-hour post-session mark, raising questions about longer-term outcomes).
11. Colorado Sun, Colorado Prepares Rollout of Psychedelic-Assisted Therapies in 2025 (Nov. 19, 2024), https://coloradosun.com/2024/11/19/colorado-psychedelic-assisted-therapies/ (noting general facilitators screen clients; persons taking antipsychotic medications must see a clinical facilitator who can provide a higher level of care).
12. Cusker et al. v. Oregon Health Authority, No. 6:2024cv00998 (D. Or. May 30, 2025) (Kasubhai, J., denying motion to dismiss); Filter, Lawsuit Seeking Psilocybin Home-Care in Oregon Permitted to Proceed (June 6, 2025), https://filtermag.org/lawsuit-psilocybin-home-care-oregon/ (12-page ruling issued late May 2025; ADA applies to Oregon psilocybin program); Marijuana Moment, Federal Judge Allows Lawsuit Seeking Home Psilocybin Care To Proceed (June 5, 2025), https://www.marijuanamoment.net/federal-judge-allows-lawsuit-seeking-home-psilocybin-care-to-proceed-rejecting-oregon-officials-motion-to-dismiss.
13. Filter, supra note 12 (quoting court: “The Court agrees with Plaintiffs and finds that their requested remedy rests on physical access rather than use or distribution of a controlled substance in violation of state and federal laws.”); Reason, New Ruling Moves Oregon Closer to Legal In-Home Psilocybin Use (June 4, 2025), https://reason.com/2025/06/04/new-ruling-moves-oregon-closer-to-legal-in-home-psilocybin-use/ (discussing court’s reliance on Smith v. 116 S Market LLC analogy).
14. Filter, Oregon Trying to Dodge Lawsuit on Dying Patients’ Psilocybin Access (Oct. 21, 2025), https://filtermag.org/oregon-psilocybin-terminally-ill-access/ (OHA filed Motion for Judgment on the Pleadings in October 2025 — procedurally distinct from the earlier motion to dismiss — arguing plaintiffs lack standing to raise ADA claims on behalf of their disabled clients); Marijuana Moment, Oregon Officials Seek To Dismiss Psilocybin Access Lawsuit From Homebound Patients (Oct. 26, 2025), https://www.marijuanamoment.net/oregon-officials-seek-to-dismiss-psilocybin-access-lawsuit-from-homebound-patients.
15. Psychedelic Alpha, The Oregon Psilocybin Services Tracker, supra note 1 (only 23 of 35 licensed service centers operational in Q3 2025; 12 closures since early 2024).
16. Id. (key factors in closures: $10,000 annual license fee, mandated security infrastructure, stringent storage protocols, and declining product prices); Willamette Week, Oregon’s Psychedelic Service Centers Are Closing Amid High Costs and Tough Regulation (June 3, 2025), https://www.wweek.com/news/2025/06/03/oregons-psychedelic-service-centers-are-closing-amid-high-costs-and-tough-regulation/.
17. Willamette Week, supra note 16 (OHA required to draw $3.1 million from general fund for 2023–25 biennium; OHA spokeswoman Erica Heartquist confirming no legislative funding for 2025–27 and need to evaluate increasing licensing fees); Willamette Week, Taxpayers May Soon Be Filling the Funding Gaps in Oregon’s Psilocybin System (May 24, 2023), https://www.wweek.com/news/2023/05/24/taxpayers-may-soon-be-filling-the-funding-gaps-in-oregons-psilocybin-system/ (OHA requesting $6.6 million from general fund for 2025–27 biennium in a policy option package submitted to the Legislature).
18. Emerge Law Group, Oregon Psilocybin Services Rule Changes: Effective January 1, 2025 (Dec. 16, 2024), https://emergelawgroup.com/blog/oregon-psilocybin-services-rule-changes-effective-january-1-2025/ (noting new compliance investigation rule among January 1, 2025 rule changes).
19. Oregon Health Authority, OPS Summer Newsletter 2023, https://content.govdelivery.com/accounts/ORDHS/bulletins/364151c (“OPS will investigate complaints, incidents, or concerns related to safety issues or statute and rule violations that occur on licensed premises and during the provision of psilocybin services”).
20. Oregon Health Authority, Oregon Psilocybin Services — Administrative Rules, supra note 4 (temporary rule effective August 29, 2025, amending OAR 333-333-4300(6) to prohibit authorized temporary uses after 11:59 PM; OPS discovered an unintended loophole in service center hours-of-operation rules; temporary rules adopted as permanent January 22, 2026).
21. Oregon Health Authority, 2023 Rulemaking, https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-2023-rulemaking.aspx (describing RAC process with multiple meetings, racial and fiscal impact evaluations, and substantial public comment; 2023 RACs addressed technical fixes, SB 303 implementation, and facilitator training requirements); Oregon Health Authority, Rules Advisory Committees (RACs), https://prod.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-rules-advisory-committees.aspx (describing RAC structure and public participation opportunities).
22. Oregon Health Authority, 2023 Rulemaking, supra note 21 (RACs include racial and fiscal impact evaluation of proposed rules).
23. Oregon Health Authority, Oregon Psilocybin Services — Administrative Rules, https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-administrative-rules.aspx (describing rulemaking process as “informed by” OPAB recommendations, RAC input, and public comment; noting OPS sends letters to OPAB about decisions made on OPAB recommendations after each rulemaking cycle); Oregon Health Authority, Oregon Psilocybin Services — Oregon Psilocybin Advisory Board, https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-advisory-board-meetings.aspx (listing OPAB recommendations to OHA and OHA letters to OPAB describing disposition of recommendations; OPAB has no independent enforcement authority under ORS 475A).
24. Psychedelic Alpha, Natural Medicine Advisory Bulletin #8: January 2024 (Feb. 16, 2024), https://psychedelicalpha.com/news/natural-medicine-advisory-bulletin-8-january-2024 (NMAB officially adopted 123 formal recommendations on January 19, 2024 — culmination of eight months and 75 meetings; recommendations to be converted into draft rules by DORA and DOR).
25. Colorado Department of Natural Medicine, Rulemaking, https://dnm.colorado.gov/rulemaking (NMD hosted public rulemaking meetings between March and July 2024 to create implementation rules; coordinated closely with NMAB and DORA throughout process).
26. Vicente LLP, Colorado Psychedelics Program: Natural Medicine Advisory Bulletin 15 (Jan. 9, 2025), https://vicentellp.com/insights/colorado-psychedelics-program-natural-medicine-advisory-bulletin-15/ (documenting NMAB Public Health and Health Equity subcommittee adopting recommendation for private residence services on December 14, 2023; full NMAB adopting this recommendation in consolidated recommendations in January 2024).
27. Id. (describing DORA’s November 15, 2024 late changes to at-home facilitation rules, made just days before the November 19 final rulemaking hearing; characterizing the changes as potentially violating Colorado’s administrative notice requirements; documenting stakeholder and NMAB concerns about circumvention of the public rulemaking process).
28. Id. (describing DORA’s reversal of controversial changes before final submission; subsequent December 13, 2024 new rulemaking notice specifically addressing at-home facilitation and microdosing).
29. Filter, New Mexico to Accelerate Launch of Therapeutic Psilocybin Access (Dec. 11, 2025), https://filtermag.org/new-mexico-accelerate-psilocybin-access/ (inaugural Medical Psilocybin Advisory Board meeting December 5, 2025).
30. Id. (describing board composition including Indigenous advocate; DOH announcing accelerated implementation timeline).
31. Cal. S.B. 1012, 2023–2024 Reg. Sess. (not enacted), https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240SB1012 (proposing Board of Regulated Psychedelic Facilitators; Expert Oversight Committee with annual public reporting on implementation of recommendations; complaint and disciplinary process for facilitator misconduct).
32. Psychedelic Alpha, Oregon Psilocybin Services Tracker: Q1 2025, supra note 7 (adverse event reporting is client-initiated; no requirement for facilitator-initiated proactive follow-up after 72-hour mark).
33. Gerd Flodgren et al., External Inspection of Compliance with Standards for Improved Healthcare Outcomes, Cochrane Database of Systematic Reviews, Issue 12 (2016), https://pmc.ncbi.nlm.nih.gov/articles/PMC6464009/ (systematic review finding very low certainty evidence that external inspection improves healthcare quality outcomes, as opposed to compliance with documented standards; review authors highlighting the paucity of high-quality controlled evaluations of inspection effectiveness and noting that inspection-based approaches are most effective for verifiable structural process standards rather than relationship-based professional conduct).
34. Harris Sliwoski LLP, Oregon Psilocybin: State of the State (2024), https://harris-sliwoski.com/psychlawblog/oregon-psilocybin-state-of-the-state-2024/ (noting OHA began publishing quarterly data beginning mid-2025; data shared with Oregon Health and Science University pursuant to ORS 475A.372).
35. Psychedelic Alpha, The Oregon Psilocybin Services Tracker, supra note 1.
36. Id. (noting service center closures must be triangulated from licensing records; opt-out provision affects demographic data completeness).
37. Cusker et al. v. Oregon Health Authority, No. 6:2024cv00998 (D. Or. May 30, 2025), supra note 12; Psychedelic Week, Oregon Psilocybin Suit for Disability Access May Proceed Says U.S. Court (June 2, 2025), https://www.psychedelicweek.com/p/oregon-psilocybin-federal-suit-disability-ada-home-access.
38. 42 U.S.C. § 12132 (Title II ADA prohibition on discrimination by public entities); 28 C.F.R. § 35.130(b)(7) (requiring public entities to make reasonable modifications unless doing so would result in a fundamental alteration or undue burden).
39. Psychedelic Week, supra note 37 (describing Colorado DORA’s proposed limitation of home services to palliative care patients and the broader ADA accommodation implications for persons with other qualifying disabilities).
40. Willamette Week, supra note 16; Willamette Week, Taxpayers May Soon Be Filling the Funding Gaps, supra note 17 (documenting general fund dependency, $3.1 million drawn for 2023–25 biennium, $6.6 million requested for 2025–27, and licensing fee revenue remaining below program costs through Q3 2025).
41. Colorado General Assembly, SB25-297 — Implementation of Colorado Natural Medicine Initiative (signed June 3, 2025), https://leg.colorado.gov/bills/SB25-297; Reason Foundation, State Psychedelics Legalization and Policy Roundup — June 2025 (updated Nov. 20, 2025), https://reason.org/commentary/state-psychedelics-legalization-and-policy-roundup-june-2025/ (Governor Polis signed SB 297 on June 3, 2025; healing centers required to send data to state by July 1, 2026).